Table 5.

Crude incidences of recurrent VTE in patients with a prior history of VTE

Risk factor profileEINSTEIN EXTENSIONEINSTEIN CHOICEEINSTEIN CHOICEEINSTEIN EXTENSION and EINSTEIN CHOICEEINSTEIN EXTENSIONEINSTEIN CHOICE
Rivaroxaban 20 mg (N = 110)Rivaroxaban 20 mg (N = 198)Rivaroxaban 10 mg (N = 197)All rivaroxaban (N = 505)Placebo (N = 88)Aspirin (N = 194)
Unprovoked, n/N (%) 0/54 (0.0) 3/78 (3.9) 2/73 (2.8) 5/205 (2.4) 2/40 (5.0) 10/76 (13.2) 
Provoked by major persistent risk factors, n/N (%) 0/2 (0.0) 0/5 (0.0) 0/7 (0.0) 0/14 (0.0) 1/10 (10.0) 
Provoked by minor persistent risk factors, n/N (%) 1/45 (2.2) 0/93 (0.0) 0/95 (0.0) 1/233 (0.4) 2/42 (4.8) 6/84 (7.1) 
Provoked by minor transient risk factors, n/N (%) 0/7 (0.0) 0/20 (0.0) 0/15 (0.0) 0/42 (0.0) 0/4 (0.0) 0/15 (0.0) 
Provoked by major transient risk factors, n/N (%) 0/2 (0.0) 0/2 (0.0) 0/7 (0.0) 0/11 (0.0) 0/2 (0.0) 0/9 (0.0) 
Risk factor profileEINSTEIN EXTENSIONEINSTEIN CHOICEEINSTEIN CHOICEEINSTEIN EXTENSION and EINSTEIN CHOICEEINSTEIN EXTENSIONEINSTEIN CHOICE
Rivaroxaban 20 mg (N = 110)Rivaroxaban 20 mg (N = 198)Rivaroxaban 10 mg (N = 197)All rivaroxaban (N = 505)Placebo (N = 88)Aspirin (N = 194)
Unprovoked, n/N (%) 0/54 (0.0) 3/78 (3.9) 2/73 (2.8) 5/205 (2.4) 2/40 (5.0) 10/76 (13.2) 
Provoked by major persistent risk factors, n/N (%) 0/2 (0.0) 0/5 (0.0) 0/7 (0.0) 0/14 (0.0) 1/10 (10.0) 
Provoked by minor persistent risk factors, n/N (%) 1/45 (2.2) 0/93 (0.0) 0/95 (0.0) 1/233 (0.4) 2/42 (4.8) 6/84 (7.1) 
Provoked by minor transient risk factors, n/N (%) 0/7 (0.0) 0/20 (0.0) 0/15 (0.0) 0/42 (0.0) 0/4 (0.0) 0/15 (0.0) 
Provoked by major transient risk factors, n/N (%) 0/2 (0.0) 0/2 (0.0) 0/7 (0.0) 0/11 (0.0) 0/2 (0.0) 0/9 (0.0) 

or Create an Account

Close Modal
Close Modal